<DOC>
	<DOCNO>NCT01228682</DOCNO>
	<brief_summary>A Drug Utilisation Survey perform monitor document drug utilisation pattern Samsca routine medical practice . A Post-Authorisation Safety Study perform collect information safety Samsca use real-life setting .</brief_summary>
	<brief_title>Post-Authorisation Safety Study Samsca ( Tolvaptan ) Used Routine Medical Practice</brief_title>
	<detailed_description>Drug Utilisation Survey The drug utilisation analysis describe number prescription , distribution different medical specialty , indication use compare SmPC , patient age patient gender distribution prescription level . In addition , indication use categorise - SIADH - Non-SIADH hyponatraemia - Non-Hyponatraemia Post-Authorisation Safety Study Sodium level baseline rate sodium correction therapy analyse . Safety finding describe . The number non-serious serious adverse event relative frequency analyse consideration risk category : - Renal safety - Aquaresis-related adverse effect - Serum sodium correction rate - Glucose homeostasis - Cardiovascular safety hemodynamics - Respiratory system - Drug metabolism drug interaction - Drug exposure pregnancy - Paediatric safety Subgroup analyse perform safety finding indication subgroup ( SIADH indication ) , subgroups accord SIADH-underlying disease , age group , hepatically impaired patient renally impaired patient .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients treat Samsca Patients sign data consent form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Sodium</keyword>
	<keyword>SIADH</keyword>
	<keyword>Hyponatremia</keyword>
	<keyword>Vasopressin</keyword>
	<keyword>Salt</keyword>
	<keyword>Water</keyword>
</DOC>